| 1 |
33200682 | Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules. | 2022 May |
1 |
| 2 |
34459458 | Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature. | 2022 Jan 1 |
3 |
| 3 |
34875133 | Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. | 2022 May |
2 |
| 4 |
34964940 | Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study. | 2022 Jan |
5 |
| 5 |
35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | 2022 May 4 |
1 |
| 6 |
35200557 | ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. | 2022 Jan 28 |
1 |
| 7 |
35233056 | Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. | 2022 Mar 1 |
1 |
| 8 |
35252896 | Unusual Resistance Mechanisms in a Case of ROS 1-Rearranged NSCLC: A Case Report. | 2022 Mar |
2 |
| 9 |
35284560 | ROS1 fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report. | 2022 Feb |
3 |
| 10 |
35299735 | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR-ROS1 Fusion. | 2022 |
3 |
| 11 |
35343863 | An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021). | 2022 Jun |
1 |
| 12 |
35361870 | Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. | 2022 Mar 31 |
3 |
| 13 |
35368001 | ROS1-Rearranged Lung Cancer Successfully Resected after Response to Crizotinib: A Case Report. | 2022 Feb 8 |
2 |
| 14 |
35506104 | Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation. | 2022 Jan |
2 |
| 15 |
35510711 | Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001. | 2022 May 5 |
1 |
| 16 |
35529295 | Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report. | 2022 Jan-Apr |
3 |
| 17 |
35574423 | Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion. | 2022 |
2 |
| 18 |
35619747 | Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma. | 2022 |
3 |
| 19 |
35628598 | A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan. | 2022 May 21 |
5 |
| 20 |
32833135 | Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels. | 2021 Feb |
1 |
| 21 |
32918045 | SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. | 2021 Jun |
5 |
| 22 |
33000474 | Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report. | 2021 Mar |
4 |
| 23 |
33001162 | Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy. | 2021 Jan 1 |
1 |
| 24 |
33386152 | Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment. | 2021 Feb |
1 |
| 25 |
33472762 | Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion. | 2021 Mar |
1 |
| 26 |
33676017 | Crizotinib in Patients With MET-Amplified NSCLC. | 2021 Jun |
1 |
| 27 |
33682977 | Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay. | 2021 Jun |
3 |
| 28 |
33685866 | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. | 2021 May 15 |
5 |
| 29 |
33841676 | Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study. | 2021 |
5 |
| 30 |
33917039 | Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics. | 2021 Apr 7 |
1 |
| 31 |
33945921 | Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion. | 2021 |
2 |
| 32 |
33994796 | A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. | 2021 |
2 |
| 33 |
34055614 | Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer. | 2021 |
1 |
| 34 |
34076666 | Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. | 2021 Jul 1 |
1 |
| 35 |
34110462 | Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. | 2021 Aug |
1 |
| 36 |
34125313 | ROS1 Targeted Therapies: Current Status. | 2021 Jun 14 |
1 |
| 37 |
34157012 | Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors. | 2021 Jul 1 |
1 |
| 38 |
34211840 | Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report. | 2021 |
2 |
| 39 |
34235088 | Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report. | 2021 |
2 |
| 40 |
34319660 | A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. | 2021 Sep |
1 |
| 41 |
34405544 | Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report. | 2021 Oct |
2 |
| 42 |
34418561 | Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. | 2021 Dec |
1 |
| 43 |
34509095 | Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. | 2021 Oct |
1 |
| 44 |
34511132 | Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. | 2021 Sep 13 |
7 |
| 45 |
34516041 | BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report. | 2021 Dec |
9 |
| 46 |
34551905 | Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. | 2021 Dec 15 |
1 |
| 47 |
34582848 | Stereospecific inhibition of AMPK by (R)-crizotinib induced changes to the morphology and properties of cancer and cancer stem cell-like cells. | 2021 Nov 15 |
1 |
| 48 |
34616749 | Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib. | 2021 |
6 |
| 49 |
34623764 | Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report. | 2021 Nov |
2 |
| 50 |
34631105 | Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report. | 2021 Nov |
2 |